Again, that has to do with methodology. The use of randomized trials always takes precedence over a study as large as 2.7 million women.
It is shocking; I completely agree with you. Those recent studies looked at more modern diagnoses and treatments using more up-to-date technology. This, I think, has to do with a lack of expertise and the lack of knowledge about what screening is and how it functions in Canadian programs. Canadian programs are extremely well run. We monitor the abnormal recall rates and the positive biopsy rates.
All of that was done and shown in this beautiful study, but because we didn't have experts who understood the impact of this, it was downgraded in favour of the randomized trials that were 60 years old.